New Ratings (DOV, DEPO, EMR, EXAS, FOSL, GPRO, LII, MNTA, OSUR, SNTA, VVUS)

Published on Thursday, 05 January 2012 08:51 Written by Danny Miller

New York, January 5^th (TradersHuddle.com) – Following are some of the new analyst ratings before the market open.

Dover (NYSE:DOV), the maker of specialized industrial products and manufacturing equipment, was initiated with Underweight at Morgan Stanley.

DepoMed (NASDAQ:DEPO) was initiated with Outperform at JMP Securities.

Emerson (NYSE:EMR), the electric motor maker, was initiated with Overweight at Morgan Stanley.

EXACT Sciences (NASDAQ:EXAS) was initiated with Outperform at JMP Securities.

Fossil (NASDAQ:FOSL), the designer and marketer of consumer fashion accessories, was initiated with a Buy and a target price of $105 at KeyBanc Capital Markets.

Gen-Probe (NASDAQ:GPRO) was initiated with a Buy at ThinkEquity.

Lennox International (NYSE:LII), the provider of climate control solutions for heating, air conditioning and refrigeration markets, was initiated with Underweight at Morgan Stanley.

Momenta Pharmaceuticals (NASDAQ:MNTA) was initiated with an Outperform at Bernstein.

OraSure Technologies (NASDAQ:OSUR) was initiated with a Buy at ThinkEquity.

Synta Pharmaceuticals (NASDAQ:SNTA) was initiated with a Market Outperform at and a target price of $8 Rodman & Renshaw.

Vivus (NASDAQ:VVUS) was initiated with a Market Perform at Rodman & Renshaw.